EVLO Evelo Biosciences Inc

Price (delayed)

$10.42

Market cap

$556.41M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.22

Enterprise value

$490.3M

Highlights
EVLO's EPS is up by 18% year-on-year
Evelo Biosciences's debt has surged by 76% YoY and by 38% QoQ
EVLO's equity is down by 29% from the previous quarter and by 10% YoY

Key stats

What are the main financial stats of EVLO
Market
Shares outstanding
53.4M
Market cap
$556.41M
Enterprise value
$490.3M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
8.96
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$106.29M
EBITDA
-$102.44M
Free cash flow
-$80.7M
Per share
EPS
-$2.22
Free cash flow per share
-$1.51
Book value per share
$1.16
Revenue per share
$0
TBVPS
$2.72
Balance sheet
Total assets
$145.06M
Total liabilities
$82.97M
Debt
$57.22M
Equity
$62.09M
Working capital
$106.57M
Liquidity
Debt to equity
0.92
Current ratio
6.38
Quick ratio
6.23
Net debt/EBITDA
0.65
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-89%
Return on equity
-190.2%
Return on invested capital
-206.7%
Return on capital employed
-84.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EVLO stock price

How has the Evelo Biosciences stock price performed over time
Intraday
7.2%
1 week
3.07%
1 month
-19.47%
1 year
156.65%
YTD
-13.81%
QTD
-24.16%

Financial performance

How have Evelo Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$103.51M
Net income
-$109.77M
Gross margin
N/A
Net margin
N/A
Evelo Biosciences's net income has decreased by 25% YoY and by 11% from the previous quarter
Evelo Biosciences's operating income has decreased by 18% YoY and by 8% from the previous quarter

Growth

What is Evelo Biosciences's growth rate over time

Valuation

What is Evelo Biosciences stock price valuation
P/E
N/A
P/B
8.96
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
EVLO's EPS is up by 18% year-on-year
EVLO's equity is down by 29% from the previous quarter and by 10% YoY
EVLO's price to book (P/B) is 20% lower than its last 4 quarters average of 10.4

Efficiency

How efficient is Evelo Biosciences business performance
The return on equity has declined by 35% year-on-year and by 15% since the previous quarter
EVLO's ROIC is up by 20% YoY but it is down by 2.2% QoQ
Evelo Biosciences's return on assets has decreased by 4.1% QoQ

Dividends

What is EVLO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EVLO.

Financial health

How did Evelo Biosciences financials performed over time
EVLO's total assets is 75% higher than its total liabilities
The company's total liabilities has surged by 86% YoY and by 27% QoQ
EVLO's total assets is up by 27% YoY but it is down by 5% QoQ
Evelo Biosciences's debt is 8% lower than its equity
EVLO's debt to equity has soared by 96% QoQ and by 96% YoY
Evelo Biosciences's debt has surged by 76% YoY and by 38% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.